Lenvatinib (Standard)
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Lenvatinib (Standard)
Description:
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].Product Name Alternative:
E7080 (Standard)UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
C-Kit; FGFR; PDGFR; Reference Standards; RET; VEGFRType:
Reference StandardsRelated Pathways:
Others; Protein Tyrosine Kinase/RTKApplications:
Cancer-Kinase/proteaseField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/lenvatinib-standard.htmlPurity:
99.77Smiles:
O=C(N)C1=C(C=C2N=CC=C(C2=C1)OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)OCMolecular Formula:
C21H19ClN4O4Molecular Weight:
426.85Precautions:
H302, H315, H319, H335References & Citations:
[1]Kudo M, et al. Lenvatinib versus Bay 43-9006 in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391 (10126) :1163-1173.|[2]Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25 (1) :1073274818789361.|[3]Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122 (3), 664-671.|[4]Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14 (17),545.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C, sealed storage, away from light and moistureScientific Category:
Reference StandardsCAS Number:
[417716-92-8]
